Polytope DNA vaccine development against hepatitis C virus: A streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice

Protein and Peptide Letters

Volumn 16, Issue 7, 2009, Pages 842-850

  MemarnejadA , Arash ^a   Roohvand, Farzin ^a   Arashkia, Arash ^a   Rafati, Sima ^b   Shokrgozar, Mohammad Ali ^c  

^a Hepatitis and AIDS Department NRGB Lab   (Iran)

^b Molecular Immunology and Vaccine Research Lab   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

DNA vaccine; Expression optimization; HBsAg; Hepatitis C virus; Polytope vaccine; Virus like particle

Indexed keywords

DNA; DNA VACCINE; EPITOPE; HEPATITIS B SURFACE ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOLOGY; CATTLE; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; FEMALE; GENETICS; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; MOUSE; NUCLEOTIDE SEQUENCE; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CATTLE; CERCOPITHECUS AETHIOPS; COMPUTATIONAL BIOLOGY; COS CELLS; DNA; EPITOPES; FEMALE; HEPACIVIRUS; HEPATITIS B SURFACE ANTIGENS; HUMANS; HYPERSENSITIVITY, DELAYED; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, DNA;

ANIMALIA; HEPATITIS C VIRUS; MUS; MUS MUSCULUS;

EID: 67849111911     PISSN: 09298665     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986609788681788     Document Type: Article

References (53)

1. Guidotti, L.G.; Chisari, F.V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol., 2006, 1, 23-61.
2. Moradpour, D.; Brass, V.; Gosert, R.; Wolk, B.; Blum, H.E. Hepatitis C: molecular virology and antiviral targets. Trends Mol. Med., 2002, 8(10), 476-482
3. Dustin, L.B.; Rice, C.M. Flying under the rader: the immunobiology of hepatitis C. Annu. Rev. Immunol., 2007, 25, 71-99.
4. Vertuani, S.; Bazzaro, M.; Gualandi, G.; Micheletti, F.; Marastoni, M.; Fortini, C.; Canella, A.; Marino, M.; Tomatis, R.; Traniello, S.; Gavioli, R. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur. J. Immunol., 2002, 32(1), 144-154
5. Zein, N.N. Clinical significance of HCV genotypes. Clin. Microbiol. Rev., 2000, 13(2), 223-235
6. Cui, Z. DNA vaccine. Adv. Genet., 2005, 54, 257-289
7. Li, X.; Yang, X.; Jiang, Y.; Liu, J. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice. Int. Immunol., 2005, 17(10), 1293-1302.
8. Takada, A.; Kawaoka, Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev. Med. Virol., 2003, 13(6), 387-398
9. Yao, Z.Q.; Eisen-Vandervelde, A.; Waggoner, S.N.; Cale, E.M.; Hahn, Y.S. Direct binding of hepatitis C virus core to gC1qR on CD4+ and CD8+ T cells leads to impaired activation of Lck and Akt. J. Virol., 2004, 78(12), 6409-6419
10. Sarobe, P.; Lasarte, J.J.; Casares, N.; Lopez-Diaz de, C.A.; Baixeras, E.; Labarga, P.; Garcia, N.; Borràs-Cuesta, F.; Prieto, J. Abnormal priming of CD4(+) T-cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J. Virol., 2002, 76(10), 5062-5070
11. Crotta, S.; Stilla, A.; Wack, A.; D'Andrea, A.; Nuti, S.; D'Oro, U.; Mosca, M.; Filliponi, F.; Brunetto, R.M.; Bonino, F.; Abrignani, S.; Valiante, N.M. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med., 2002, 195(1), 35-41.
12. Dolganiuc, A.; Kodys, K.; Kopasz, A.; Marshall, C.; Do, T.; Romics, L., Jr.; Mandrekar, P.; Zapp, M.; Szabo, G. Hepatitis C virus core and nonstructural protein 3 proteins induce pro-and antiinflammatory cytokines and inhibit dendritic cell differentiation. J. Immunol., 2003, 170(11), 5615-5624
13. Suhrbier, A. Polytope vaccines for the co-delivery of multiple CD8 T-cell epitopes. Expert Rev. Vaccines, 2002, 1(2), 207-213
14. Sette, A.; Livingston, B.; McKinney, D.; Appella, E.; Fikes, J.; Sidney, J.; Newman, M.; Chesnut, R. The development of multiepitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals, 2001, 29(3-4), 271-276
15. Shirai, M.; Chen, M.; Arichi, T.; Masaki, T.; Nishioka, M.; Newman, M.; Nakazawa, T.; Feinstone, S.M.; Berzofsky, J.A. Use of an intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. J. Infect. Dis., 1996, 173(1), 24-31.
16. Leroux-Roels, G. Development of prophylactic and therapeutic vaccines against hepatitis C virus. Expert Rev. Vaccines, 2005, 4(3), 351-371
17. Sarobe, P.; Huarte, E.; Lasarte, J.J.; de Cerio, L.; Garcia, N.; Borràs-Cuesta, F.; Prieto, J. Characterization of an immunologically conserved epitope from hepatitis C virus E2 glycoprotein recognized by HLA-A2-restricted cytotoxic T-lymphocytes. J. Hepatol., 2001, 34(2), 321-329
18. Lohr, H.F.; Schmitz, D.; Arenz, M.; Weyer, S.; Gerken, G.; Meyer zum Büschenfelde, K.H. The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T-cell frequencies. J. Hepatol., 1999, 31(3), 407-415
19. Thimme, R.; Oldach, D.; Chang, K.M.; Steiger, C.; Ray, S.C.; Chisari, F.V. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med., 2001, 194(10), 1395-1406.
20. Deml, L.; Bojak, A.; Steck, S.; Graf, M.; Wild, J.; Schirmbeck, R.; Wolf, H.; Wagner, R. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J. Virol., 2001, 75(22), 10991-11001.
21. Horton, R.M.; Hunt, H.D.; Ho, S.N.; Pullen, J.K.; Pease, L.R. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene, 1989, 77(1), 61-68
22. Baez-Astua, A.; Herraez-Hernandez, E.; Garbi, N.; Pasolli, H.A.; Juarez, V.; Zur, H.H.; Cid-Arregui, A. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type-16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses. J. Virol., 2005, 79(20), 12807-12817
23. Puaux, A.L.; Marsac, D.; Prost, S.; Singh, M.K.; Earl, P.; Moss, B.; Le, G.R.; Riviere, Y.; Michel, M.L. Efficient priming of simian/ human immunodeficiency virus (SHIV)-specific T-cell responses with DNA encoding hybrid SHIV/hepatitis B surface antigen particles. Vaccine, 2004, 22(27-28), 3535-3545
24. Towbin, H.; Staehelin, T.; Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Biotechnology, 1992, 24, 145-149
25. Loi, P.K.; Mcgraw, H.F.; Tublitz, N.J. Peptide detection in single cell using a dot immunoblot assay. Peptides, 1997, 18(5), 749-753
26. Radhakrishnan, S.; Abraham, P.; Sridharan, G. Improved sensitivity of reverse transcriptase polymerase chain reaction for hepatitis C virus using random hexamer primers. Diagn. Microbiol. Infect. Dis., 1999, 33(3), 153-156
27. Sambrook, J.; Russell, D.W. In Molecular Cloning, a Laboratory Manual, Sambrook and Russell, Ed.; CSHL Press, New York, 2001; Vol. 3, pp. 17.48-17.51.
28. Leenars, P.P.A.M.; Hendriksen, C.F.M.; de Leeuw, W.A.; Carat, F.; Delahaut, P.; Fischer, R. The production of polyclonal antibodies in laboratory animals, the report and recommendations of ECVAM workshop 35. ATLA Abstr., 1999, 27, 79-102.
29. Kundig, T.M.; Althage, A.; Hengartner, H.; Zinkernaget, R.M. Skin test to assess virus-specific cytotoxic T-cell activity. Proc. Natl. Acad. Sci. USA, 1992, 89(16), 7757-7761
30. Zali, M.R.; Mayumi, M.; Raoufi, M.; Nowroozi, A. HCV genotypes in the Islamic Republic of Iran: preliminary study. East. Mediterr. Health J., 2000, 6(2-3), 372-377
31. Zein, N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev., 2000, 13(2), 223-235
32. Yewdell, J.W.; Bennink, J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol., 1999, 17, 51-88.
33. Shirai, M.; Arichi, T.; Nishioka, M.; Nomura, T.; Ikeda, K.; Kawanishi, K.; Engelhard, V.H.; Feinstone, S.M.; Berzofsky, J.A. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLAA2.1. J. Immunol., 1995, 154(6), 2733-2742
34. Himoudi, N.; Abraham, J.D.; Fournillier, A.; Lone, Y.C.; Joubert, A.; De Beeck, A.O.; Freida, D.; Lemonnier, F.; Kieny, M.P.; Inchauspé, G. Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection. J. Virol., 2002, 76(24), 12735-12746
35. Park, S.H.; Yang, S.H.; Lee, C.G.; Youn, J.W.; Chang, J.; Sung, Y.C. Efficient induction of T helper-1 CD4+ T-cell responses to hepatitis C virus core and E2 by a DNA prime-adenovirus boost. Vaccine, 2003, 21(31), 4555-4564
36. Livingston, B.D.; Newman, M.; Crimi, C.; McKinney, D.; Chesnut, R.; Sette, A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine, 2001, 19(32), 4652-4660
37. Groot, A.D.; Sbai, H.; Aubin, C.S.; McMurray, J.; Martin, W. Immuno-informatics: Mining genomes for vaccine components. Immunol. Cell Biol., 2002, 80, 255-269
38. Garmory, H.S.; Freeman, D.; Brown, K.A.; Titball, R.W. Protection against plague afforded by immunization with DNA vaccines optimized for expression of the Yersinia pestis V antigen. Vaccine, 2004, 22(8), 947-957
39. Andre, S.; Seed, B.; Erberle, J.; Schraut, W.; Bultmann, A.; Haas, J. Increased immune response elicited by DNA vaccination with a synthetic gp 120 sequence with optimized codon usage. J. Virol., 1998, 72(2), 1497-1503
40. Stratford, R.; Douce, G.; Zhang-Barber, L.; Fairweather, N.; Eskola, J.; Dougan, G. Influence of codon usage on the immunogenicity of a DNA vaccine against tetanus. Vaccine, 2000, 19(7-8), 810-815
41. Bellier, B.; Delba, C.; Clerc, B.; Desjardins, D.; Drury, R.; Cosset, F.; Collins, M.; Klatzmann, D. DNA vaccines encoding retrovirusbased virus-like particles induce efficient immune responses without adjuvant. Vaccine, 2006, 24(14), 2643-2655
42. Grgacic, E.V.; Anderson, D.A. Virus-like particles: passport to immune recognition. Methods, 2006, 40(1), 60-65
43. Jin, H.; Xiao, W.; Xiao, C.; Yu, Y.; Kang, Y.; Du, X.; Wei, X.; Wang, B. Protective immune responses against foot-and-mouth disease virus by vaccination with a DNA vaccine expressing viruslike particles. Viral Immunol., 2007, 20(3), 429-440
44. Netter, H.J.; Macnaughton, T.B.; Woo, W.P.; Tindle, R. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes. J. Virol., 2001, 75(5), 2130-2141
45. Michel, M.L.; Mancini, M.; Sobczak, E.; Favier, V.; Guetard, D.; Bahraoui, E.M.; Tiollais, P. Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV-hepatitis B surface antigen particles. Proc. Natl. Acad. Sci. USA, 1988, 85(21), 7957-7961
46. Lee, I.H.; Kim, C.H.; Ryu, W.S. Presentation of the hydrophilic domains of hepatitis C viral E2 envelope glycoprotein on hepatitis B surface antigen particles. J. Med. Virol., 1996, 50(2), 145-151
47. Delpeyroux, F.; Chenciner, N.; Lim, A.; Lambert, M.; Malpiece, Y.; Streeck, R.E. Insertions in the hepatitis B surface antigen. Effect on assembly and aecretion of 22-nm particles from mammalian cells. J. Mol. Biol., 1987, 195(2), 343-350
48. Delpeyroux, F.; Van Wezel, F.; Blondel, B.; Crainic, R. Structural factors modulate the activity of antigenic poliovirus sequences expressed on hybrid hepatitis B surface antigen particles. J. Virol., 1990, 64(12), 6090-6100
49. Galvin, T.A.; Muller, J.; Khan, A.S. Effect of different promoters on immune responses elicited by HIV-1 gag/env multigenic DNA vaccine in Macaca mulatta and Macaca nemestrina. Vaccine, 2000, 18(23), 2566-2583
50. Xiang, Z.Q.; Spitalnik, S.L.; Cheng, J.; Erickson, J.; Wojczyk, B.; Ertl, H.C.G. Immune responses to nucleic acid vaccines to rabies virus. Virology, 1995, 209(2), 569-579
51. Xu, Z.-L.; Mizuguchi, H.; Ishii-Watabe, A.; Uchida, E.; Mayumi, T.; Hayakawa, T. Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene, 2001, 272(1-2), 149-156
52. Yu, D.; Amano, C.; Fukuda, T.; Yamada, T.; Kuroda, S.; Tanizawa, K.; Kondo, A.; Ueda, M.; Yamada, H.; Tada, H.; Seno, M. The specific delivery of proteins to human liver cells by engineered bio-nanocapsules. FEBS J., 2005, 272(14), 3651-3660
53. Sureau, C.; Fournier-Wirth, C.; Maurel, P. Role of N glycosylation of hepatitis B virus envelope proteins in morphogenesis and infectivity of hepatitis delta virus. J. Virol., 2003, 77(9), 5519-5523.